Stock data
| Market cap. | €47m |
| Last close | €1.27 |
| High / Low (52 weeks) | €2.6 / €0.9 |
| Stock market listing | Deutsche Borse |
| Forecast net cash (€m) | 5.4 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 23.851 | 29.286 | (50.508) |
| Relative * | 15.898 | 4.605 | (47.077) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2009A | 2.8 | (24.1) | (26.3) | (77.0) | N/A | N/A |
| 2010A | 2.3 | (17.3) | (17.3) | (47.2) | N/A | N/A |
| 2011E | 4.1 | (11.4) | (13.4) | (33.3) | N/A | 7.3 |
| 2012E | 5.0 | (11.8) | (12.2) | (30.1) | N/A | N/A |
Last updated on 27/01/2012
Latest research
Rapid facts expected
Update | Pharmaceutical & Healthcare | 27/01/2012
Warts and all
Outlook | Pharmaceutical & Healthcare | 05/01/2012
Investment summary
A dynamically designed clinical formulation study of MediGene’s rheumatoid arthritis project, RhuDex, has begun and should yield data around the middle of this year. If positive, this should allow RhuDex to progress swiftly into further clinical development that could later spur partnering discussions. Our valuation model is unchanged, and the upside for MediGene hinges on a successful partnering deal for EndoTAG-1 and perhaps RhuDex – its key R&D assets.
Last updated on 27/01/2012
Key management
| Dr. Frank Mathias , CEO |
| Arnd Christ, CFO |
Company address
| Lochhamer Str. 11 Martinsried 82152 Germany +49-89-85 65-29 00 View website |
